{
    "2021-02-19": [
        [
            {
                "time": "",
                "original_text": "A,D,C,抗体偶联药物进入爆发期，恒瑞、荣昌生物、高瓴等抢占百亿市场",
                "features": {
                    "keywords": [
                        "抗体偶联药物",
                        "爆发期",
                        "恒瑞",
                        "荣昌生物",
                        "高瓴",
                        "百亿市场"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "生物医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": ""
                }
            },
            {
                "time": "",
                "original_text": "6个新冠疫苗品种已开展III期临床试验，疫苗股业绩飙升，如何布局？",
                "features": {
                    "keywords": [
                        "新冠疫苗",
                        "III期临床试验",
                        "疫苗股",
                        "业绩飙升"
                    ],
                    "sentiment_score": 0.85,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药",
                        "疫苗"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "",
                "original_text": "68只港股获南向资金大比例持有",
                "features": {
                    "keywords": [
                        "港股",
                        "南向资金",
                        "大比例持有"
                    ],
                    "sentiment_score": 0.75,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2021-02-19",
                "original_text": "智通港股通持股分析|2月19日",
                "features": {
                    "keywords": [
                        "智通",
                        "港股通",
                        "持股分析"
                    ],
                    "sentiment_score": 0.6,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [],
                    "causal_factor": "false",
                    "causal_impact": "",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "neutral"
                }
            }
        ]
    ]
}